I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

The prevalence of diabetes in United Arab Emirates is estimated to be 12.6%, affecting 768 thousand people.\[[@ref1]\] Fear of hypoglycaemia and gain in body weight act as barriers for initiation of insulin therapy.\[[@ref2]\] Modern insulin analogues are a convenient new approach or tool to glycaemic control, associated with low number of hypoglycaemia and favourable weight change.\[[@ref3]\] A~1~chieve, a multinational, 24-week, non-interventional study, assessed the safety and effectiveness of insulin analogues in people with T2DM (*n* = 66,726) in routine clinical care.\[[@ref4]\] This short communication presents the results for patients enrolled from Dubai.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

Please refer to editorial titled: The A~1~chieve study: Mapping the Ibn Battuta trail.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

A total of 767 patients were enrolled in the study. The patient characteristics for the entire cohort divided as insulin-naïve and insulin users is shown in the [Table 1](#T1){ref-type="table"}. Glycaemic control at baseline was poor in this population. The majority of patients (48.1%) started on or were switched to insulin detemir. Other groups were insulin aspart (*n* = 29), basal insulin plus insulin aspart (*n* = 111), Biphasic insulin aspart (*n* = 231) and other insulin combinations (*n* = 26). After 24 weeks of treatment, overall hypoglycaemic events reduced from 5.6 events/patient-year to 2.4 events/patient-year in insulin user group whereas hypoglycaemia increased from 0.1 events/patient-year to 0.8 events/patient-year in insulin naive group. However, this hypoglycaemia incidence in insulin naive group at 24 weeks was still lower than that observed in insulin users at baseline. SADRs did not occur in any of the study patients. Major hypoglycaemia was nil similar to that of baseline in insulin naïve group whereas major hypoglycaemic events reduced from 0.3 events/patient-year to 0.1 events/patient-year in insulin users. Blood pressure decreased and overall lipid profile improved at week 24 in the cohort \[Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}\].
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Overall demographic data
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Overall safety data
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###### 

Insulin dose
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All parameters of glycaemic control improved from baseline to study end in the total cohort. \[[Table 4](#T4){ref-type="table"}\].

###### 

Overall efficacy data
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Biphasic insulin aspart ± OGLD {#sec2-1}
------------------------------

Of the total cohort, 231 patients started on biphasic insulin aspart ± OGLD, of which 110 (47.6%) were insulin naïve and 121 (52.4%) were insulin users. After 24 weeks of starting or switching to biphasic insulin aspart, hypoglycaemic events reduced from 6.0 events/patient-year to 2.6 events/patient-year in insulin user group, while hypoglycaemia increased from 0.1 events/patient-year to 1.1 events/patient-year in insulin users group. An increase in body weight was also observed at the end of the study \[Tables [5](#T5){ref-type="table"} and [6](#T6){ref-type="table"}\].

###### 

Biphasic insulin aspart±oral glucose-lowering drug safety data
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###### 

Insulin dose
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All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to biphasic insulin aspart for both insulin naïve and insulin user groups \[[Table 7](#T7){ref-type="table"}\].

###### 

Biphasic insulin aspart±oral glucose-lowering drug efficacy data
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Basal + insulin aspart ± OGLD {#sec2-2}
-----------------------------

Of the total cohort, 111 patients started on basal + insulin aspart ± OGLD was 111, of which 39 (35.1%) were insulin naïve and 72 (64.9%) were insulin users. After 24 weeks of starting or switching to basal + insulin aspart, hypoglycaemic events reduced from 6.3 events/patient-year to 4.3 events/patient-year in insulin user group, whereas hypoglycaemic events increased from 0.0 events/patient-year to 3.6 events/patient-year in insulin naïve group. A decrease in body weight was observed in insulin naïve group at the end of the study \[Tables [8](#T8){ref-type="table"} and [9](#T9){ref-type="table"}\].

###### 

Basal+insulin aspart±oral glucose-lowering drug safety data
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###### 

Insulin dose
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All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to basal + insulin aspart ± OGLDs for both insulin naïve and insulin user groups \[[Table 10](#T10){ref-type="table"}\].

###### 

Basal+insulin aspart±oral glucose-lowering drug efficacy data
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Insulin detemir ± OGLD {#sec2-3}
----------------------

Of the total cohort, 369 patients started on insulin detemir ± OGLD was 369, of which 315 (85.4%) were insulin naïve and 54 (14.6%) were insulin users. After 24 weeks of starting or switching to insulin detemir, hypoglycaemic events reduced from 5.3 events/patient-year to 0.8 events/patient-year in insulin user group, whereas hypoglycaemia increased from 0.2 events/patient-year to 0.4 events/patient-year in insulin naïve group. A decrease in body weight was also observed at the end of the study \[Tables [11](#T11){ref-type="table"} and [12](#T12){ref-type="table"}\].

###### 

Insulin detemir±oral glucose-lowering drug safety data
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###### 

Insulin dose
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All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin detemir ± OGLDs for both insulin-naïve and insulin user groups \[[Table 13](#T13){ref-type="table"}\].

###### 

Insulin detemir±oral glucose-lowering drug efficacy data
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Insulin aspart ± OGLD {#sec2-4}
---------------------

Of the total cohort, 29 patients started on insulin aspart ± OGLD, of which 8 (27.6%) were insulin naïve and 21 (72.4%) were insulin users. After 24 weeks of treatment starting or switching to insulin aspart, hypoglycaemic events reduced from 1.9 events/patient-year to 0.0 events/patient-year in insulin user group whereas no change in hypoglycaemia was observed in insulin naïve group similar to that of baseline. An increase in body weight was observed in insulin user group at the end of the study \[Tables [14](#T14){ref-type="table"} and [15](#T15){ref-type="table"}\].

###### 

Insulin aspart±oral glucose-lowering drug safety data
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###### 

Insulin dose
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All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin aspart ± OGLDs for both insulin naïve and insulin user groups \[[Table 16](#T16){ref-type="table"}\].

###### 

Insulin aspart±oral glucose-lowering drug efficacy data
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C[ONCLUSION]{.smallcaps} {#sec1-4}
========================

Our study reports improved glycaemic control following 24 weeks of treatment with any of the insulin analogues (Biphasic insulin aspart; basal + insulin aspart; insulin detemir; insulin aspart) with or without OGLD. All four insulin regimens showed a decrease in HbA~1~c, FPG and PPPG, this improvement was higher in insulin naïve group compared to insulin users group. SADRs did not occur in any of the study patients. Major hypoglycaemia was nil similar to that of baseline in insulin naïve group whereas major hypoglycaemic events reduced from 0.3 events/patient-year to 0.1 events/patient-year in insulin users. A small weight reduction was observed in insulin naive group. Though the findings are limited by number of patients, still the trend indicates that insulin analogues can be considered effective and possess a safe profile for treating type 2 diabetes in Dubai.
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